Transcranial Magnetic Stimulation for Stroke Recovery

Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique that uses electromagnetic induction to generate electrical currents in targeted brain regions. Over the past two decades, repetitive TMS (rTMS) has emerged as a promising adjunctive therapy for stroke rehabilitation, with the strongest evidence supporting its use for upper limb motor recovery and post-stroke aphasia. Unlike implanted vagus nerve stimulation, rTMS is not FDA-approved specifically for stroke rehabilitation, but it has received “Level A” evidence rating for motor recovery in clinical guidelines.

🔹 Bottom Line: TMS for Stroke Recovery

  • Evidence level: “Level A” specifically for low-frequency rTMS of contralesional M1 for hand motor recovery in the post-acute phase (Lefaucheur 2020); strong meta-analytic support for post-stroke aphasia.
  • Mechanism: Rebalances interhemispheric inhibition — excitatory stimulation to ipsilesional cortex or inhibitory stimulation to contralesional cortex.
  • Protocols: High-frequency rTMS (≥5 Hz) or iTBS to ipsilesional M1; low-frequency rTMS (1 Hz) or cTBS to contralesional M1.
  • Theta burst stimulation (TBS): Achieves similar effects in ~3 minutes vs 20–30 minutes for conventional rTMS.
  • Best used as adjunct: Combined with physical/occupational therapy or speech-language therapy — not as standalone treatment.
  • FDA status: Not FDA-approved for stroke rehabilitation; FDA-cleared for treatment-resistant depression.

Mechanism of Action

The therapeutic rationale for TMS in stroke recovery is based on the interhemispheric inhibition model. After unilateral stroke, the balance between hemispheres is disrupted: the contralesional (unaffected) hemisphere becomes relatively overactive and exerts excessive inhibition on the damaged ipsilesional hemisphere through transcallosal pathways. This maladaptive plasticity may impede recovery.

TMS can rebalance hemispheric activity through two complementary strategies:

  • Excitatory stimulation (high-frequency rTMS or iTBS) applied to the ipsilesional primary motor cortex (M1) → increases cortical excitability and motor output from the affected hemisphere
  • Inhibitory stimulation (low-frequency rTMS or cTBS) applied to the contralesional M1 → reduces excessive inhibition from the unaffected hemisphere

Both approaches aim to enhance neuroplasticity and promote functional reorganization in motor and language networks. The effects are mediated through long-term potentiation (LTP) and long-term depression (LTD)-like mechanisms at the synaptic level.

Types of TMS Protocols

Protocol Frequency Target Effect Duration Pulses
HF-rTMS 5–20 Hz Ipsilesional M1 Excitatory 20–30 min 1,000–2,000
LF-rTMS 1 Hz Contralesional M1 Inhibitory 20–30 min 1,200–1,800
iTBS 50 Hz bursts at 5 Hz Ipsilesional M1 Excitatory ~3 min 600
cTBS 50 Hz continuous bursts Contralesional M1 Inhibitory ~40 sec 600

🔹 Clinical Relevance: Why Theta Burst Stimulation?

  • Time efficiency: iTBS delivers 600 pulses in ~3 minutes vs 20–30 minutes for conventional rTMS
  • Similar efficacy: Meta-analyses show comparable motor improvements to conventional protocols
  • Patient comfort: Shorter sessions improve tolerability and compliance
  • Cost-effectiveness: More patients can be treated per day
  • Ongoing trials: B-STARS2 (phase 3, 454 patients) is evaluating cTBS as standard of care

Applications in Stroke Recovery

Upper Limb Motor Recovery

Motor recovery has the strongest evidence base for TMS in stroke rehabilitation. Multiple meta-analyses demonstrate significant improvements in upper limb function with both conventional rTMS and theta burst protocols.

Key evidence:

  • B-STARS trial (2023): 60 patients randomized to cTBS vs sham within 3 weeks of stroke. cTBS significantly improved Action Research Arm Test (ARAT) scores at 3 months (+12.8 points vs +5.0 points) with benefits sustained at 12 months.
  • High-dose TBS trial (2024): Neuroimaging-guided iTBS and cTBS both outperformed sham on FMA-UE at 3 weeks (p<0.01). cTBS showed particular benefit in chronic stroke patients.
  • Meta-analysis (2024): 382 participants across 10 studies showed significant FMA-UE improvements with rTMS (SMD 1.28, 95% CI 1.08–1.48).
  • Systematic review (2025): rTMS improves post-stroke motor outcomes across multiple domains, with strongest effects in acute/subacute phase.

🔹 Clinical Relevance: Timing Matters

  • Subacute phase (1–12 weeks): Greatest potential for benefit; enhanced neuroplasticity window
  • Chronic phase (>3 months): Still beneficial but effect sizes may be smaller
  • Acute phase (<1 week): Limited data; safety concerns about early intervention
  • MEP status: Patients with preserved motor evoked potentials may respond better, though MEP-negative patients can still benefit

Post-Stroke Aphasia

rTMS has emerged as a valuable adjunct to speech-language therapy (SLT) for post-stroke aphasia, particularly non-fluent aphasia. The primary approach uses inhibitory 1 Hz rTMS over the right pars triangularis (Broca’s area homolog) to reduce compensatory right hemisphere recruitment.

Key evidence:

  • Meta-analysis (2024, 47 RCTs, 2,190 patients): rTMS significantly improved naming, repetition, spontaneous speech, and auditory comprehension in non-fluent aphasia. Also reduced post-stroke depression symptoms.
  • NORTHSTAR-CA trial: Compared rTMS + SLT vs sham + SLT in subacute and chronic aphasia. Significant naming improvement with rTMS in subacute patients only (median 1.91 vs 1.02 Z-score improvement, p=0.046). Chronic patients showed no additional benefit over SLT alone.
  • M-MAT combination trial (2025): 1 Hz rTMS + 35 hours of multimodality aphasia therapy over 10 days was safe and feasible in chronic aphasia, though results were comparable to sham + therapy.

🔴 Important: Aphasia TMS Considerations

  • rTMS appears most beneficial in subacute phase (5–45 days post-stroke) for aphasia
  • Chronic aphasia patients may benefit more from intensive SLT alone
  • Always combine with speech-language therapy — rTMS is an adjunct, not standalone
  • Lesion location may affect response; personalized targeting may be needed

Post-Stroke Depression

High-frequency rTMS (10–20 Hz) applied to the left dorsolateral prefrontal cortex (DLPFC) has established efficacy for major depression and can be considered for post-stroke depression. The 2026 AHA/ASA acute stroke guidelines reference rTMS as a potential adjunctive therapy for post-stroke depression based on systematic review evidence.

Lower Limb and Balance

Evidence for lower limb recovery is less robust than for upper limb. Recent meta-analyses suggest:

  • Cerebellar iTBS: May improve Berg Balance Scale scores more effectively than M1 stimulation for lower limbs
  • iTBS to lower limb M1: Shows trends toward improvement in FMA-LE and walking performance but less consistent than upper limb data

Patient Selection

Factor Consideration Evidence
Timing post-stroke Subacute (1–12 weeks) may have greatest benefit Multiple trials show larger effects in earlier phases
Stroke type Both ischemic and hemorrhagic B-STARS included both; similar responses
MEP status Preserved MEPs may predict better response Some trials show greater benefit in MEP+ patients
Lesion location Subcortical lesions may respond better than large cortical Cortical M1 damage may limit ipsilesional stimulation efficacy
Severity Moderate impairment (some residual function) Complete paralysis shows less response
Cognition Ability to participate in paired rehabilitation TMS alone without therapy is less effective

Practical Protocol Considerations

🔹 Practical Workflow: rTMS for Motor Recovery

Step 1: Patient Evaluation

  • Screen for contraindications (see below)
  • Baseline motor assessment (FMA-UE, ARAT, grip strength)
  • Determine MEP status if available

Step 2: Motor Threshold Determination

  • Resting motor threshold (RMT) measured from contralesional M1
  • If no MEP from ipsilesional side, use mirror location at 100% contralesional RMT
  • Stimulation typically delivered at 80–120% RMT

Step 3: Target Localization

  • Anatomical landmarks (5 cm anterior to vertex) or
  • Neuronavigation with MRI for precise targeting
  • Hotspot determination for optimal MEP response

Step 4: Treatment Sessions

  • Typically 10–20 sessions over 2–4 weeks
  • Daily sessions (5 days/week) most common
  • Immediately followed by rehabilitation therapy (OT/PT)

Step 5: Reassessment

  • Post-treatment motor assessment
  • Follow-up at 1–3 months to assess durability

Safety and Contraindications

🔴 Absolute Contraindications

  • Implanted metallic hardware in or near the head (excluding titanium)
  • Cochlear implants
  • Deep brain stimulators or other implanted neurostimulators
  • Implanted medication pumps
Relative Contraindications Consideration
History of seizures/epilepsy Increased seizure risk; may still be used with caution
Skull defects/craniectomy Altered current distribution; avoid stimulating near defect
Pregnancy Limited safety data; generally avoided
Severe cardiovascular disease Rare vagal effects reported
Medications lowering seizure threshold TCAs, antipsychotics, stimulants — assess risk/benefit

Common side effects:

  • Headache: Most common (5–20%); usually mild and transient
  • Scalp discomfort: At stimulation site; improves with sessions
  • Transient hearing changes: Use of earplugs recommended
  • Seizure: Very rare (<0.1%); slightly higher with high-frequency protocols

Comparison: TMS vs Other Neuromodulation for Stroke

Modality Mechanism Invasiveness FDA Status (Stroke) Evidence Level
rTMS/TBS Electromagnetic induction Non-invasive Not approved Level A (motor)
tDCS Direct current polarization Non-invasive Not approved Level B
Implanted VNS Vagal neuromodulation Surgical implant FDA approved (Vivistim) Level A
ta-VNS Transcutaneous vagal Non-invasive Investigational Emerging
Cerebellar DBS Deep brain stimulation Highly invasive Investigational Early phase
Spinal cord stimulation Epidural stimulation Invasive Investigational Early phase

🔹 TMS vs VNS: How to Choose?

  • TMS: Non-invasive, no surgery required, widely available, requires frequent clinic visits (10–20 sessions), no home use
  • VNS: Requires surgical implantation, FDA-approved, enables home-based ongoing therapy, higher upfront cost, durable long-term effects
  • Consider TMS if: Patient prefers non-invasive approach, subacute phase, facility has TMS capability, trial of neuromodulation before committing to implant
  • Consider VNS if: Chronic stroke (≥9 months), moderate impairment (FMA-UE 20–40), willing to undergo surgery, wants home-based long-term therapy

Limitations and Knowledge Gaps

  • Protocol heterogeneity: Optimal frequency, intensity, duration, and target not standardized
  • Individual variability: Significant inter-individual differences in response; biomarkers to predict responders needed
  • Limited long-term data: Most trials report outcomes at 3 months; durability beyond 1 year unclear
  • No FDA approval for stroke: Unlike VNS, rTMS remains off-label for stroke rehabilitation
  • Access and cost: Requires specialized equipment and trained personnel; not universally available
  • Combination protocols: Optimal pairing with specific rehabilitation therapies not established

Key Trials Summary

Trial/Study Year Protocol Population N Key Finding
B-STARS 2023 cTBS contralesional M1 Subacute stroke (<3 wks) 60 ARAT +12.8 vs +5.0 at 3 mo (p<0.05)
High-dose TBS 2024 iTBS/cTBS neuroimaging-guided Subacute/chronic 60 Both iTBS and cTBS superior to sham
Kim et al. 2020 1 Hz LF-rTMS contralesional Subacute ischemic 54 FMA-UE improved; effects at 3 mo
rTMS + fMRI 2018 HF vs LF vs sham Early stroke (<2 wks) 60 Both HF and LF improved FMA-UE vs sham
Aphasia meta-analysis 2024 Various rTMS protocols Non-fluent aphasia 2,190 Improved naming, repetition, spontaneous speech
NORTHSTAR-CA 2022 1 Hz rTMS + SLT Subacute vs chronic aphasia 67 Benefit in subacute only; not chronic
iTBS balance 2024 Cerebellar iTBS Stroke with imbalance 290 BBS improved; cerebellar > M1 target
B-STARS2 (ongoing) 2024– cTBS phase 3 Subacute stroke 454 Primary endpoint: FMA-UE at 90 days

Conclusion

Transcranial magnetic stimulation represents a promising non-invasive neuromodulation approach for stroke rehabilitation, with the strongest evidence supporting its use for upper limb motor recovery and post-stroke aphasia. Both conventional rTMS and the more time-efficient theta burst protocols can enhance outcomes when combined with rehabilitation therapy. While not yet FDA-approved specifically for stroke, rTMS has achieved “Level A” evidence for motor recovery and is increasingly integrated into comprehensive stroke rehabilitation programs. The ongoing B-STARS2 phase 3 trial will provide pivotal data on whether cTBS should become standard of care. For now, TMS offers a valuable non-invasive option for patients seeking to augment their recovery, particularly in the critical subacute window when neuroplasticity is greatest.

References

  1. Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol. 2020;131:474–528.
  2. Vink JJT, et al. Continuous theta-burst stimulation of the contralesional primary motor cortex for promotion of upper limb recovery after stroke: a randomized controlled trial. Brain Stimul. 2023.
  3. Cheng J, et al. Repetitive transcranial magnetic stimulation for post-stroke non-fluent aphasia: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2024;15:1348695.
  4. Zumbansen A, et al. Differential effects of speech and language therapy and rTMS in chronic versus subacute post-stroke aphasia: results of the NORTHSTAR-CA trial. Neurorehabil Neural Repair. 2022;36(4):291–302.
  5. Lin F, Hamilton RH, Sloane KL. Repetitive transcranial magnetic stimulation for post-stroke rehabilitation: a systematic review and meta-analysis. medRxiv. 2025.
  6. Chen K, et al. Effect of theta burst stimulation on lower extremity motor function improvement and balance recovery in patients with stroke. Medicine. 2024;103(44):e40098.
  7. Vink JJT, et al. B-STARS2: Early contralesional continuous theta burst stimulation (cTBS) to promote upper limb recovery after stroke – rationale and design of a phase-3 multicentre trial. Int J Stroke. 2025.
  8. Prabhakaran S, et al. 2026 Guideline for the early management of patients with acute ischemic stroke. Stroke. 2026;57:xxx–xxx.